Company intelligence
Aradigm
Benefits platform for cell and gene therapies designed to provide sustainable access to life-saving medicines.
About Aradigm
Aradigm is a benefits platform for cell and gene therapies (CGT) designed to provide sustainable access to life-saving medicines. Our novel financial and delivery model addresses the challenges facing every stakeholder—payers, providers, manufacturers, and, most importantly, patients. By creating a large-scale risk pool to cover and pay for all CGT drugs and care, with unspent funds returned, we can deliver cost predictability for employers and health plans. Our end-to-end experience includes a national network of "centers of excellence” and concierge patient support, giving providers volume and rate certainty and patients appropriate, high-quality treatment and outcomes.
Verified activity
Signals from Aradigm
3 published signals
Legal & Regulatory
Aradigm CEO William Shrank, MD, MSHS, wrote about the approval of two genetic therapies by the FDA in December 2023 for sickle cell disease.
Reported by Aradigm
Legal & Regulatory
Aradigm CEO William Shrank, MD, MSHS, wrote about CMS launching the Cell and Gene Therapy Access Model in July 2025 to facilitate CGTs for Medicaid beneficiaries across participating states.
Reported by Aradigm
Presence & Recognition
Aradigm co-founder Annie Collins joined host John Shufeldt, MD, JD, MBA, FACEP, on a recent episode of Entrepreneur Rx to discuss the economics of cell and gene therapy, payers, and patient access.
Reported by Aradigm